



**25<sup>th</sup> DCVMN Annual General Meeting**  
**Theme: Steering Change to Augment Vaccine Access**  
**&**  
**Environmental Sustainability**

*16<sup>th</sup>-18<sup>th</sup> October, 2024 | São Paulo, Brazil*

Provisional Programme as on 23<sup>rd</sup> July, 2024

*Pre-AGM Day: Tuesday, 15<sup>th</sup> October, 2024*

Local Time	Program Structure and Schedule
<b>1000-1700</b>	<b>Registrations for AGM</b>
<b>1200-1300</b>	<b>DCVMN Board Meeting (Internal)</b>
<b>1400-1830</b>	<b>Visit to Vaccine Museum and Science Park, Instituto Butantan (pre-registration required, please stand-by for details)</b>

*Program Day 1: Wednesday, 16<sup>th</sup> October, 2024*

Local Time	Program Structure and Schedule	
<b>0800-0830</b>	<b>Registrations for General Assembly (GA) designated voting nominees (for Member Companies only)</b>	
<b>0830-1030</b>	<b>General Assembly, Parallel Sessions and Registrations for AGM to continue</b>	
<b>0830-1030</b>	<b>0830-1030 Parallel Sessions</b>	<b>0830-1030 Registrations for AGM continues.</b>
<b>General Assembly</b> <i>(for designated voting nominees from member companies only)</i>	<b>0830-0900</b> <b>Session by Zebra/ Temptime</b> <b>Speaker:</b> Mr. Jon Pearman, Supranational Consultant- Temptime, a Zebra Technologies Company <b>Topic:</b> VVM supporting new vaccine rollout and regional production	
	<b>0900-0930</b> <b>Session by Tofflon Group</b> <b>Speaker:</b> Mr. Karl Yu, Business Development Manager	



	<p><b>Topic:</b> Recombinant protein vaccine platform based on Hybrid technology</p> <p><b>0930-1000</b> <b>Session by Merck</b> <b>Speaker:</b> Mr. Juan Francisco Amor, Technical Application Specialist, Merck</p> <p><b>Topic:</b> Improved endotoxin removal using ecofriendly detergents: Intensified plasmid DNA capture</p> <p><b>1000-1030</b> <b>Session by Rommelag</b> <b>Speakers:</b> Dr. Matthew Peters, Engineering &amp; Business Development, New Horizons (invited by Rommelag) Mr. Tim Kram, Managing Director, Rommelag USA</p> <p><b>Topic:</b> Vaccine Wastage Reduction &amp; Vaccine Packaging</p>	
<b>1030-1050</b>	<b>Networking Break over Coffee</b>	
<b>1100-1230</b>	<b>Inaugural Session</b>	
	<ul style="list-style-type: none"> <li>• Initiation of Ceremony, Rajinder Suri, CEO-DCVMN</li> <li>• Opening Address, Mr. Adriansjah Azhari, Board Chair-DCVMN</li> <li>• Welcome by Co-host, Prof. Esper Georges Kallás, Director-Instituto Butantan</li> <li>• Welcome by Co-host, Dr. Mauricio Zuma Medeiros, CEO-Bio Manguinhos/Fiocruz</li> </ul> <p><b>Invited Speakers:</b></p> <ul style="list-style-type: none"> <li>• Dr. Tedros Adhanom Ghebreyesus, DG-WHO</li> <li>• Dr. Sania Nishtar, CEO-GAVI</li> <li>• Dr. Richard Hatchett, CEO-CEPI</li> <li>• Dr. Jarbas Barbosa da Silva Jr., Director-PAHO</li> <li>• Ms. Leila Ghargozloo Pakkala, Director-UNICEF SD</li> <li>• H.E. Dr. Jean Kaseya, Director General-Africa CDC</li> <li>• Dr. Ayode Alakija, Board Chair-FIND</li> <li>• Keynote address by the Guest of Honor, Honorable Minister of Health Dr. Nísia Trindade Lima</li> <li>• Inaugural address by the Chief Guest, H.E. Luiz Inácio Lula da Silva, Honorable President of Brazil</li> <li>• Vote of thanks by Dr. Saulo Simoni Nacif, Executive Director-Fundação Butantan</li> </ul>	
<b>1230-1330</b>	<b>Networking Lunch</b>	



<b>1330-1430</b>	<p><b>Session 1   Global PPPR &amp; Equitable Access to LICs</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Bruce Aylward, Assistant Director-General, Universal Health Coverage, Life Course, WHO</li> <li>• Dr. Richard Hatchett, CEO-CEPI</li> <li>• Dr. Seth Berkley, Global Health Consultant-Berkley Consultants, SA (SFB)</li> <li>• Mr. Guilherme Cintra, Director, Innovation Policy-IFPMA</li> <li>• Dr. Judit Rius Sanjuan, Director IMT-PAHO</li> <li>• Mr. Derrick Sim, Managing Director, Vaccine Markets &amp; Health Security-GAVI</li> <li>• Prof. Padmashree Gehl Sampath, Chief Executive Officer-African Pharmaceutical Technology Foundation</li> <li>• Prof. Petro Terblanche, CEO-Afrigen</li> <li>• Ms. Zeynep Kantur Ozenci, Global Sector Manager, Global Head of Health-IFC</li> <li>• Dr. Andrew O. Jones, Principal Advisor &amp; Chief Vaccine Center-UNICEF SD</li> <li>• Dr. Frauke Uekermann, Director Vaccine Markets-CHAI</li> </ul> <p>Audience Q&amp;A</p>
<b>1430-1500</b>	<p><b>Novel Technologies supporting Global Immunization</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Mauricio Zuma Medeiros, CEO-Bio Manguinhos/Fiocruz</li> <li>• Presentation by Temptime, a Zebra Technologies company-Mr. Brandon Ball, Head of Government Affairs Topic: Good for Governments, People, and Climate</li> <li>• Presentation by Tofflon-Mr. Vikrant Hedau, Technical Director Topic: Flexible &amp; Fast Track Vaccine Manufacturing platform</li> </ul>
<b>1500-1520</b>	<b>Networking Break over Coffee</b>
<b>1530-1630</b>	<p><b>CEO Forum-Strategic direction of DCVMN Horizon 2050</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Prof. Esper Georges Kallás, Director- Instituto Butantan</li> <li>• Dr. Amadou Alpha Sall, CEO-Institut Pasteur de Dakar</li> <li>• Ms. Mahima Datla, Managing Director &amp; CEO-Biological E</li> <li>• Dr. Mauricio Zuma Medeiros, CEO-Bio-Manguinhos/Fiocruz</li> <li>• Dr. Morena Makhoana, CEO-Biovac</li> <li>• Mr. Hun Kim, President-SK Bioscience</li> <li>• Dr. Abdul Muktedir, Chairman &amp; MD-Incepta Pharma &amp; Vaccines</li> <li>• Dr. Xuefeng Yu, Chairman &amp; CEO-CanSino Biologics Inc.</li> </ul> <p>Audience Q&amp;A</p>
<b>1630-1700</b>	<b>DCVMN CEO's Report</b>
<b>1930 onwards</b>	<b>Networking Cocktail</b>



**25th  
DCVMN**

17<sup>th</sup> October, 2024

Program Day 2: Thursday,

ANNUAL GENERAL MEETING

Local Time		Program Structure and Schedule			
<b>0800-0850</b>	<b>Parallel Sessions</b>				
<b>0800-0840</b>	<b>DCVMN Board &amp; CEOs f2f interaction with Dr. Bruce Aylward, ADG, UHC, Life Course-WHO</b>	<b>0800-0825</b>	<b>Parallel Session by USP</b> Dr. Laura B. Martin, Vaccines Program Director, Global Health Technical Programs, USP Topic: Bridging Regulatory Gaps: Navigating Vaccine Approval in LMICs	<b>0825-0850</b>	<b>Parallel Session by Adjuvant Capital</b>
<b>0900-1000</b>	<b>Session 2   Regulatory Harmonization and Clinical Development leading to Timely Access of Vaccines in LICs and LMICs</b>				
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Yukiko Nakatani, Assistant Director-General, Access to Medicines and Health Products-WHO</li> <li>• Dr. Rogério Gaspar, Director of Regulation and Prequalification-WHO</li> <li>• Dr. Maria Luz Pombo, Unit Chief, Quality and Regulation of Medicines and Health Technologies (IMT/QR), Innovation, Access to Medicines and Health Technologies (IMT) PAHO/WHO-PAHO</li> <li>• Dr. David Kaslow, Director Office of Vaccine Research and Review-CBER, USFDA</li> <li>• Dr. Antônio Barra Torres, President-Director of the Brazilian Health Regulatory Agency (Anvisa)</li> <li>• Dr. Carmen Rodriguez Hernandez, PQ Unit-WHO</li> <li>• Dr. Alexander Precioso, Pharmacovigilance Lead-CEPI</li> <li>• Dr. Rajeshwari Adhisheshan, Senior Program Officer, Chemistry Manufacturing &amp; Controls, Vaccine Development, Global Health-BMGF</li> </ul> <p>Audience Q&amp;A</p>				
<b>1000-1100</b>	<b>Session 3   Innovations in Financial Mechanisms: Influence &amp; Impact on Universal Coverage</b>				
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Mr. Farid Fezoua, Global Director Health and Education-IFC</li> <li>• Mr. Ousmane Fall, Director-AfDB</li> <li>• Mr. Juan Parodi, Lead Investment Officer-IDB Invest</li> <li>• Dr. David Robinson, Deputy Director, Chemistry, Manufacturing and Control, Clinical Vaccine Development, Global Health-BMGF</li> <li>• Ms. Tania Cernuschi, Unit Head-Agenda, Policy and Strategy (APS)-WHO</li> <li>• Ms. Nafisa Jiwani, Managing Director for Global Health Initiatives-US DFC</li> <li>• Dr. Hani Kim, Executive Director-RIGHT Foundation, South Korea</li> <li>• Mr. James Polan, Vice-President and Head of Health and Agribusiness-US DFC</li> <li>• Dr. Saulo Simoni Nacif, Executive Director-Fundação Butantan</li> </ul> <p>Audience Q&amp;A</p>				



<b>1100-1120</b>	<b>Networking Break over Coffee</b>
<b>1130-1230</b>	<b>Session 4   Priority Vaccines: Polio, TB, Dengue, Malaria and Meningitis</b>
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Birgitte Giersing, Team Lead-WHO Vaccine Product and Delivery Research Unit</li> <li>• Dr. Julio Henrique Rosa Croda, Associate Professor, Faculty of Medicine of the Federal University of Mato Grosso do Sul and the School of Public Health at Yale University, Specialist in Science, Technology and Innovation in Public Health-Oswaldo Cruz Foundation</li> <li>• Dr. Jerome H. Kim, Director General-IVI</li> <li>• Mr. Siddhartha Prakash, Head of Global Health-WIPO</li> <li>• Dr. Chunlin Xin, Vice President of external R&amp;D-CanSino Biologics Inc.</li> <li>• Dr. Umesh Shaligram, Executive Director-Serum Institute of India</li> <li>• Dr. Raches Ella, Head-Business Development &amp; Advocacy-Bharat Biotech</li> <li>• Ms. Iin Susanti Budiharto, Director for Production &amp; Supply Chain-PT BioFarma</li> </ul> <p>Audience Q&amp;A</p>
<b>1230-1330</b>	<b>Networking Lunch</b>
<b>1330-1430</b>	<b>Session 5   Private Sector Engagement to Boost Regional Manufacturing</b>
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Jicui Dong, Unit Head of the Local Production and Assistance Unit-WHO</li> <li>• Dr. Claudia, Nannei, Senior Programme Manager, Access to MHP-WHO</li> <li>• Dr. Simone Blayer, Global Head, CMC and Nonclinical Toxicology-PATH</li> <li>• Dr. Santiago Cornejo, Executive Manager-PAHO</li> <li>• Mr. Sai D. Prasad, Executive Director-Bharat Biotech</li> <li>• Dr. Stavros Nicolaou, Senior Executive-Strategic Trade-Aspen Pharmacare</li> <li>• Mr. Soleh Ayubi, Dy. CEO-PT Biofarma (Persero)</li> <li>• Ms. Farrah Losper, Commercial Director-Biovac</li> <li>• Mr. Kristopher Howard, NRL Enterprise Solutions</li> <li>• Ms. Ghada Abuzaid, Principal Industrial Program Coordinator-AfDB</li> </ul> <p>Audience Q&amp;A</p>
<b>1430-1450</b>	<b>Networking Break over Coffee</b>
<b>1500-1600</b>	<b>Session 6   Novel Technologies</b>
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Mr. Samir Desai, President, Zydus Life Sciences</li> <li>• Presentation by Merck-Mr. Juan Franciso Amor, Technical Application Specialist Topic: Novel applications in mRNA manufacturing-Usage of ProCellics Raman Analyzer in mRNA manufacturing</li> <li>• Presentation by Rommelag USA-Mr. Tim Kram, Managing Director Topic: Novel applications for vaccine delivery utilizing Blow/Fill/Seal technology</li> <li>• Presentation by USP-Dr. Fouad Atouf, Senior Vice President, Global Biologics Topic: Quality: Supporting the vaccine product lifecycle through standards</li> <li>• Presentation by Adjuvant Capital</li> </ul> <p>Audience Q&amp;A</p>



<b>1600-1700</b>	<b>Session 7   Digital Technology and Impact of AI on Vaccine Manufacturing and Supply Chain</b>
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Mathew Downham, Director, Manufacturing and Supply Chain-CEPI</li> <li>• Dr. Sanjay Singh, CEO-Gennova</li> <li>• Ms. Rachel Park, Director of International Business-EuBiologics</li> <li>• Dr. Kapil Maithal, President - Vaccines &amp; Diagnostics-ZyduS LifeSciences</li> <li>• Mr. Charles Dalton, Global Sector Specialist Health-IFC</li> <li>• Dr. Andrew Wong, Director, Business Development-Walvax Biotechnology</li> <li>• Dr. Marcel Bassil, GCI</li> </ul> <p>Audience Q&amp;A</p>
<b>1700-1715</b>	<b>Announcement on latest initiatives by PAHO, Dr. Santiago Cornejo, Executive Manager-PAHO</b>
<b>1715-1730</b>	<b>Wrap-up by Mr. Tiago Rocca, Deputy Board Chair-DCVMN</b>
<b>1815</b>	Gathering for departure for Gala Dinner
<b>1930 onwards</b>	Gala Dinner

**Program Day 3: Friday, 18<sup>th</sup> October, 2024**

Local Time	Program Structure and Schedule
<b>0800-0840</b>	<p><b>mRNA Tech-Transfer Program by WHO/MPP</b></p> <p><b>Chair: tbc</b></p> <ul style="list-style-type: none"> <li>• Chair: Dr. Ike James, Director of Technology Transfer-MPP</li> <li>• Ms. Claudia Nannei, Senior Technical Officer-WHO</li> <li>• Prof. Petro Terblanche, CEO-Afrigen</li> <li>• Ms. Patrícia Cristina da Costa Neves, Bio-Manguinhos/Fiocruz</li> <li>• Dr. Jose Castillo, Co-founder &amp; CTO-Univercells</li> </ul> <p>Audience Q&amp;A</p>
<b>0845-0915</b>	<p><b>Africa Manufacturing Capacity Mapping 2024 by PATH-CHAI-Africa CDC</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Jens Demand, Director (Sustaining Vaccine Manufacturing)-PATH</li> <li>• Dr. Phil Dorrel, Manager Vaccine Markets-CHAI</li> <li>• Mr. Harshet Jain, General Manager Business Development-Panacea Biotec</li> <li>• Mr. Manuel Batz, Component Lead Vaccine Production, GIZ</li> </ul> <p>Audience Q&amp;A</p>



<b>0930-1010</b>	<p><b>Session 8   Impact of Climate Change, Environment Sustainability &amp; Net-Zero</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Paulo Gadelha, Coordinator of the Fiocruz Strategy for the 2030 Agenda-Bio-Manguinhos/Fiocruz</li> <li>• Dr. Jean-Pierre Amorij, Vaccine Technology Specialist-UNICEF-SD</li> <li>• Dr. Arvind Kumar, Senior Advisor-Strategic Partnerships-USAID/India</li> <li>• Dr. Ankur Mutreja, Director of Strategy, Partnerships and Communications, South Asia-PATH</li> <li>• Dr. Daniel Rodriguez, Director of Procurement-PAHO</li> <li>• Dr. Carine Fichard, Latin America and Caribbean Vaccine Study (Demand/Supply and Environment Analysis)-IFC</li> <li>• Dr. Luis Salomon, Senior Operations Officer-IFC</li> </ul> <p>Audience Q&amp;A</p>
<b>1010-1050</b>	<p><b>Session 9   Innovate: International Network for Vaccine Safety Surveillance Study</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Prof. NK Arora, Executive Director-The INCLIN Trust International</li> <li>• Dr. Alexander Precioso, Pharmacovigilance Lead-CEPI</li> <li>• Dr. Katharina Hartmann, Senior Consultant-Bluwin</li> <li>• Dr. Abhishek Agarwal, Deputy Director (Research)-The INCLIN Trust International</li> <li>• Dr. Patrícia Mouta, Safety physician, Bio-Manguinhos/Fiocruz</li> <li>• Dr. Viska Indriani, Head of Pharmacovigilance Department, PT BioPharma</li> <li>• Mr. Reza Bosman, Pharmacovigilance Officer, Biovac</li> </ul> <p>Audience Q&amp;A</p>
<b>1050-1120</b>	<p><b>Networking Break over Coffee</b></p>
<b>1120-1200</b>	<p><b>Session 10   Building Capacity: Vaccine Workforce Development Program</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Ms. Julia Kuhn, Officer, Strategy Planning and Management, Vaccine Development-BMGF</li> <li>• Ms. Amanda Zehnder, Senior OD and Change Management Advisor-PATH</li> <li>• Dr. Chiluba Mwila, PAVM Talent Development Lead-Africa CDC</li> <li>• Prof. Kelvin Lee, Professor of Chemical and Biomolecular Engineering, University of Delaware and Director-NIIMBL</li> <li>• Mr. Anil Nair, Lead-Talent Management and Organizational L&amp;D-Zydus Life Sciences</li> </ul> <p>Audience Q&amp;A</p>
<b>1200-1300</b>	<p><b>Session 11   Collaborating to Augment Vaccine Supply Chain Security</b></p> <ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Matthew Downham, Director, Manufacturing and Supply Chain-CEPI</li> <li>• Dr. Michael Karl Schunk, Senior Industry Specialist-IFC</li> <li>• Dr. Tomás Augusto Pippo, Innovations and Regional Production Platform-PAHO</li> <li>• Dr. Abebe Genetu Bayih, Acting Coordinator-PAVM</li> <li>• Ms. Jane Karonga, Economic Affairs Officer-UN Economic Commission for Africa</li> <li>• Mr. S Venkatraman, Vice President-Bharat Biotech</li> <li>• Mr. Parag Deshmukh, Director International Business-Serum Institute of India</li> <li>• Ms. Yalda Momeni, Senior Specialist, Vaccine Future Supplier Base Strategy-GAVI</li> </ul> <p>Audience Q&amp;A</p>



<b>1300-1400</b>	<b>Networking Lunch</b>
<b>1400-1440</b>	<b>Session 12   Biodefence Strategies: An insurance against Biothreats</b>
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Dr. Richard Hatchett, CEO-CEPI</li> <li>• Dr. Raman Rao, CEO-Hilleman Laboratories</li> <li>• Dr. Sushant Sahastrabuddhe, Associate Director General-CARE-IVI, South Korea</li> <li>• Dr. Ankur Mutreja, Director of Strategy, Partnerships and Communications, South Asia-PATH</li> </ul> <p>Audience Q&amp;A</p>
<b>1440-1510</b>	<b>Session 14   Counter Vaccine Hesitancy and Build Confidence</b>
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Prof. Cristiana Toscano, Institute of Tropical Pathology and Public Health-Federal University of Goiás (UFG), Brazil   Specialist in the epidemiology of infectious diseases</li> <li>• Prof. Heidi Larson, Prof. of Anthropology, Risk &amp; Decision SC-London School of Medicine and Hygiene &amp; Tropical Medicine</li> <li>• Mr. Olli Rundgren, CEO &amp; Founder-Psyon Games</li> </ul> <p>Audience Q&amp;A</p>
<b>1510-1530</b>	<b>Networking Break over Coffee</b>
<b>1530-1630</b>	<b>Session 15   Partnerships Ecosystem: Gaps, Resources and Capabilities</b>
	<ul style="list-style-type: none"> <li>• <b>Chair:</b> Ms. Jessica Milman, Global Head CVIA-PATH</li> <li>• Dr. Frederik Kristensen, Managing Director-RVMC</li> <li>• Mr. Dominic Hein, Director of Market Shaping-GAVI</li> <li>• Mr. Murat Hakan Öztürk, Supply Chain Advisor-PAHO Revolving Fund</li> <li>• Ms. Tara Lavanya Prasad, Team Lead-Global Access, APS, IVB, UHC-WHO</li> <li>• Ms. Ann Ottosen, Senior Manager-UNICEF SD</li> <li>• Mr. Sourabh Sobti, Business Development Lead-CEPI</li> <li>• Dr. Sunil Gairola, Executive Director-Serum Institute of India</li> <li>• Mr. Fernando Lobos, Director-Sinergium Biotech</li> </ul> <p>Audience Q&amp;A</p>
<b>1630-1700</b>	<b>Wrap-up by CEO-DCVMN International</b>
<b>Close of 25<sup>th</sup> DCVMN AGM</b>	

*\*Timings are subject to change; the full programme will be announced closer to the date of the AGM and will be available at [www.dcvmn.org](http://www.dcvmn.org)*

*\*Please look out for relevant meeting rooms for respective sessions*